Moore Capital Management
NAUT icon

Moore Capital Management’s Nautilus Biotechnolgy NAUT Stock Holding History

Moore Capital Management’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-50,000
Closed -$543K – 745
2020
Q4 		$543K Hold
50,000
– – 0.01% 451
2020
Q3 		$536K Buy
+50,000
New +$533K 0.01% 318

Other funds holding NAUT

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Alpha Wave Global
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
BlueCrest Capital Management
BlueCrest Capital Management St Helier, Jersey $3.04B AUM 26.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Moore Capital Management's NAUT Position: Q1 2021 in Review

Moore Capital Management sold out of Nautilus Biotechnolgy (NAUT) in Q1 2021, closing a stake of 50,000 shares — an estimated $543K sold.

Moore Capital Management first reported a position in NAUT in Q3 2020 and held it in 2 quarters. The position peaked at $543K in Q4 2020. 44 funds tracked by Wall St. Rank hold NAUT as of Q1 2021.

  • Moore Capital Management reported no remaining Nautilus Biotechnolgy position as of Q1 2021 after selling out during the quarter.
  • Moore Capital Management sold 50,000 Nautilus Biotechnolgy shares in Q1 2021, an estimated $543K.
  • Moore Capital Management first reported a position in Nautilus Biotechnolgy in Q3 2020 and held it in 2 quarters.
  • Moore Capital Management's Nautilus Biotechnolgy position peaked at $543K in Q4 2020.
  • 44 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q1 2021.

Based on Moore Capital Management's 13F filing for Q1 2021, filed 17 May 2021.